Literature DB >> 3959965

Autologous blood transfusion for elective surgery.

M D Nicholls, M R Janu, V J Davies, C E Wedderburn.   

Abstract

Between September 1983 and June 1985, 336 patients were assessed by the Autologous Blood Transfusion Service; 267 men, mean age, 65 (range, 16-75) years, and 40 women, mean age, 63 (range, 40-70) years, participated in the programme (29 patients were excluded as unsuitable). Orthopaedic and vascular surgery accounted for 80% of the cases. Complications were minor even in this elderly group. Surgical and transfusion details for a one-month period were studied retrospectively. Of the surgical cases that required crossmatched blood, 50% were for "emergency" and "burn" surgery, and 50% for elective surgery. Forty-five per cent of this latter group were unsuitable as autologous donors, 21% had participated in the autologous blood transfusion programme, and an additional 34% were deemed to be suitable donors. The realistic upper limits of our autologous blood transfusion programme were determined as being 55% of elective cases that require crossmatched blood. To be efficient an autologous blood transfusion service must be incorporated into an existing homologous blood transfusion service and must complement, rather than replace, homologous blood transfusion.

Entities:  

Mesh:

Year:  1986        PMID: 3959965     DOI: 10.5694/j.1326-5377.1986.tb128408.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  4 in total

1.  Solcotrans (R) for emergency autotransfusion.

Authors:  R Bhattacharyya
Journal:  Arch Emerg Med       Date:  1987-09

2.  The need for autologous blood transfusion.

Authors:  L A Kay
Journal:  Br Med J (Clin Res Ed)       Date:  1987-01-17

3.  Perioperative autologous blood transfusion in elective total hip prosthesis operations.

Authors:  S R Bennett
Journal:  Ann R Coll Surg Engl       Date:  1994-03       Impact factor: 1.891

4.  Autologous blood transfusion.

Authors:  J Parker-Williams
Journal:  J R Soc Med       Date:  1987-05       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.